Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Esophageal or Gastroesophageal Junction (GEJ) Carcinoma in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| PD-L1 |
|
Defined at the solid tumor level and applicable to Esophageal or Gastroesophageal Junction (GEJ) Carcinoma and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Esophageal or Gastroesophageal Junction (GEJ) Carcinoma. Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
PD-L1 (PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]); deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)